Prot #AC220-007: A Phase 3 Open-Label Randomized Study of Quizartinib (Ac220) Monotherapy versus Salvage Chemotherapy in Subjects with FLT3-ITD Positive Acute Myeloid Leukemia (AML) Refractory to or Relapsed After First-Line Treatment With or Without Hema

Project: Research project

Project Details

StatusFinished
Effective start/end date3/25/14 → 3/25/17

Funding

  • Novella Clinical, LLC (Prot #AC220-007 // Prot #AC220-007)
  • Ambit Biosciences Corporation (Prot #AC220-007 // Prot #AC220-007)